- Home
- NLSP vs SYNX Comparison
NLSP vs SYNX Comparison
Compare NLSP & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- SYNX
- Stock Information
- Founded
- NLSP 2015
- SYNX 2005
- Country
- NLSP Switzerland
- SYNX Israel
- Employees
- NLSP N/A
- SYNX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- NLSP Health Care
- SYNX
- Exchange
- NLSP Nasdaq
- SYNX Nasdaq
- Market Cap
- NLSP 12.4M
- SYNX 11.4M
- IPO Year
- NLSP 2021
- SYNX 2024
- Fundamental
- Price
- NLSP $1.95
- SYNX $1.77
- Analyst Decision
- NLSP
- SYNX
- Analyst Count
- NLSP 0
- SYNX 0
- Target Price
- NLSP N/A
- SYNX N/A
- AVG Volume (30 Days)
- NLSP 171.1K
- SYNX 102.5K
- Earning Date
- NLSP 08-12-2025
- SYNX 05-14-2025
- Dividend Yield
- NLSP N/A
- SYNX N/A
- EPS Growth
- NLSP N/A
- SYNX N/A
- EPS
- NLSP N/A
- SYNX N/A
- Revenue
- NLSP N/A
- SYNX $9,094,000.00
- Revenue This Year
- NLSP N/A
- SYNX $32.35
- Revenue Next Year
- NLSP N/A
- SYNX N/A
- P/E Ratio
- NLSP N/A
- SYNX N/A
- Revenue Growth
- NLSP N/A
- SYNX 19.14
- 52 Week Low
- NLSP $1.30
- SYNX $1.50
- 52 Week High
- NLSP $8.35
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- NLSP 37.66
- SYNX 51.25
- Support Level
- NLSP $1.71
- SYNX $1.61
- Resistance Level
- NLSP $2.00
- SYNX $1.88
- Average True Range (ATR)
- NLSP 0.15
- SYNX 0.14
- MACD
- NLSP -0.03
- SYNX 0.00
- Stochastic Oscillator
- NLSP 21.67
- SYNX 43.24
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.